Christian Gronemann

Christian Gronemann

Auto-generated profile, based on publicly available information

Christian Gronemann

Department of Neuroradiology, University Hospital Bonn, Bonn, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2024 in Neuroradiology
Verified
Journal Article
Open access
PDF file
NLNils Lehnen
Nils Lehnen
ASArndt-Hendrik Schievelkamp
Arndt-Hendrik Schievelkamp
CGChristian Gronemann
Christian Gronemann
RHRobert Haase
Robert Haase
IKInga Krause
Inga Krause
Daniel PaechDaniel Paech
Daniel Paech
Purpose: To evaluate the impact of an AI-based software trained to detect cerebral aneurysms on TOF-MRA on the diagnostic performance and reading times across readers with varying experience levels. Methods: One hundred eighty-six MRI studies were reviewed by six readers to detect cerebral aneurysms. Initially, readings were assisted by the CNN-based software mdbrain. After 6 weeks, a second reading was conducted without software assistance. The results were compared to the consensus reading of two neuroradiological specialists and sensitivity (lesion and patient level), specificity (patient level), and false positives per case were calculated for the group of all readers, for the subgroup of physicians, and for each individual reader. Also, reading times for each reader were measured. Results: The dataset contained 54 aneurysms. The readers had no experience (three medical students), 2 years experience (resident in neuroradiology), 6 years experience (radiologist), and 12 years (neuroradiologist). Significant improvements of overall specificity and the overall number of false positives per case were observed in the reading with AI support. For the physicians, we found significant improvements of sensitivity on lesion and patient level and false positives per case. Four readers experienced reduced reading times with the software, while two encountered increased times. Conclusion: In the reading with the AI-based software, we observed significant improvements in terms of specificity and false positives per case for the group of all readers and significant improvements of sensitivity and false positives per case for the physicians. Further studies are needed to investigate the effects of the AI-based software in a prospective setting.

3 October 2024 in Interventional Neuroradiology
Verified
Journal Article
Closed access
LGLukas Goertz
Lukas Goertz
SHSophia Hohenstatt
Sophia Hohenstatt
DVDominik F. Vollherbst
Dominik F. Vollherbst
CWCharlotte Sabine Weyland
Charlotte Sabine Weyland
ONOmid Nikoubashman
Omid Nikoubashman
CKChristoph Kabbasch
Christoph Kabbasch
Objective: This multicenter study evaluates the safety and efficacy of coated flow diverters (cFDs) for the treatment of cerebral aneurysms under single antiplatelet therapy (SAPT). Methods: This is a retrospective, observational study of 41 patients (median age: 58 years) with 41 aneurysms (median size: 7 mm, 29 [71%] saccular, 9 [22%] ruptured) treated with cFDs at four neurovascular centers between 2020 and 2023. Scheduled cases received continuous SAPT starting seven days before the procedure. Emergency cases were treated with tirofiban followed by SAPT loading. The safety endpoint was ischemic complications occurring during the procedure and within four months of clinical follow-up. Results: The Pipeline Vantage or Flex Shield was used in 26 (63%) procedures, the FRED X in 12 (29%), the p48/64 Hydrophilic Polymer Coating in 2 (5%), and the Derivo Embolization Device 2heal in 1 (2%). Single antiplatelet therapy consisted of prasugrel in 27 (66%) patients, ticagrelor in 9 (22%), and ASA in 5 (12%). There were 2 (5%) early ischemic complications (one minor stroke and one transient ischemic attack). There were no late ischemic complications in the four-month follow-up of 35 patients. The six dropouts included four nontreatment-related deaths after subarachnoid hemorrhage and two patients with a poor outcome after subarachnoid hemorrhage. Complete and favorable occlusion rates (median: 7 months) were 75% (27/36) and 89% (32/36), respectively. Conclusions: Coated flow diverter implantation in the setting of SAPT was safe and effective and warrants confirmation in a prospective comparative trial.

9 August 2024 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
LGLukas Goertz
Lukas Goertz
SHSophia Hohenstatt
Sophia Hohenstatt
DVDominik F. Vollherbst
Dominik F. Vollherbst
MPMuriel Pflaeging
Muriel Pflaeging
CGChristian Gronemann
Christian Gronemann
CKChristoph Kabbasch
Christoph Kabbasch
BACKGROUND AND PURPOSE: The Pipeline Embolization Device is a safe and effective treatment option for intracranial aneurysms. The newer Pipeline generations have received structural refinements and a surface modification to improve deliverability, procedural safety, and angiographic outcomes. This multicenter study evaluated the clinical safety and efficacy of the 2 surface-modified Pipeline iterations, Pipeline Vantage and Pipeline Flex with Shield Technology (PFS). MATERIALS AND METHODS: Consecutive patients treated between 2017 and 2023 were retrospectively reviewed for aneurysm characteristics, procedural details, complications, and angiographic outcomes. The safety end point was the rate of procedural and postprocedural major neurologic events occurring during the hospital stay. The efficacy end point was the rate of complete occlusion at last follow-up. RESULTS: One hundred forty-one patients underwent 112 Pipeline Vantage procedures and 32 PFS procedures for 147 aneurysms with a mean size of 8.0 (SD, 5.9) mm (11% ruptured, 16% posterior circulation, 18% nonsaccular morphology). All procedures were technically successful with a mean of 1.2 devices implanted. Balloon angioplasty was required in 20/144 (13.9%) procedures. Major neurologic adverse events occurred in 6/144 (4.2%) procedures (all ischemic stroke), resulting in death in 2 (1.4%) patients. There were no hemorrhagic complications. At a mean of 11 months, complete occlusion was achieved in 85/112 (75.9%) aneurysms, 15/112 (13.4%) had an entry remnant, and 12/112 (10.7%) had an aneurysm remnant. CONCLUSIONS: The results demonstrate high feasibility, procedural safety, and efficacy of the surface-modified Pipeline flow diverters.

31 January 2026 in Neuroradiology
Verified
Journal Article
Open access
PDF file
LGLukas Goertz
Lukas Goertz
SHSophia Hohenstatt
Sophia Hohenstatt
DVDominik F. Vollherbst
Dominik F. Vollherbst
CWCharlotte Sabine Weyland
Charlotte Sabine Weyland
ONOmid Nikoubashman
Omid Nikoubashman
CKChristoph Kabbasch
Christoph Kabbasch
Purpose Surface modifications may improve procedural safety of flow diverter (FD) treatment, but larger studies are rare. This multicenter study aims to evaluate the safety and efficacy of unruptured aneurysm treatment with surface-modified and coated FDs. Methods Patients treated with the following FDs at 8 neurovascular centers were retrospectively reviewed: Pipeline Vantage Embolization Device, Pipeline Flex with Shield Technology, FRED X, p48/64 HPC, Derivo Embolization Device (DED), and DED 2heal. Aneurysm characteristics, procedural details, and angiographic results were evaluated in detail. Results A total of 511 patients with 545 aneurysms were included (mean aneurysm size: 8.2 ± 5.5 mm, 12% posterior circulation, 14% non-saccular morphology). Multiple FDs were used in 26/515 (5%) procedures and adjunctive coiling in 76 (15%). Thromboembolic events occurred in 40 (7.8%) cases, including 9 (1.7%) major ischemic events, 20 (3.9%) minor ischemic events and 11 (2.1%) asymptomatic/technical events. Non-saccular aneurysm morphology (p = 0.014) and use of multiple FDs (p = 0.025) favored thromboembolic events. Hemorrhagic events occurred in 5 (1.0%) cases, of which 3 were symptomatic. The combined morbidity and mortality rate was 11/515 (2.1%). Complete and adequate occlusion rates were 66% (196/297) and 80% (238/297) at 6 months, respectively, and 70% (64/92) and 85% (78/92) at 12 months, respectively. Conclusion The present study demonstrates high safety and efficacy for coated or surface-modified FDs. Whether the surface modifications confer a clinical benefit needs to be addressed in comparative studies.

24 February 2025 in Interventional Neuroradiology
Verified
Journal Article
Closed access
LGLukas Goertz
Lukas Goertz
CWCharlotte Sabine Weyland
Charlotte Sabine Weyland
ONOmid Nikoubashman
Omid Nikoubashman
FBFranziska Bürkle
Franziska Bürkle
FBFrederic de Beukelaer
Frederic de Beukelaer
CKChristoph Kabbasch
Christoph Kabbasch
Objective: Phenox flow diverters (p64 and its smaller vessel variant p48) represent an established treatment option for intracranial aneurysms. This study evaluates the safety and efficacy of the new generation of these devices with an additional antithrombotic surface coating (HPC). Methods: Consecutive patients treated between 2020 and 2023 at three institutions were retrospectively reviewed for aneurysm characteristics, procedural details, complications, and angiographic outcomes. Results: Sixty-one patients (mean age 56 years) were treated for 61 aneurysms. The mean aneurysm size was 8.3 ± 4.9 mm, 12 (19.7%) were ruptured, 16 (26.2%) were recurrent after previous treatment, 10 (16.4%) were located in the posterior circulation, and 7 (11.5%) had nonsaccular morphology. All procedures were technically successful, with a single device sufficient in 60/61 (98%) cases. Delivery problems included device twisting in one case and incomplete proximal opening in another. Additional angioplasty was performed in 3/61 (4.9%) procedures and additional coiling in 4 (6.6%). There were 3 (4.9%) major events (1 thromboembolic ischemic stroke, 1 fatal intracranial hemorrhage, and 1 delayed aneurysm rupture) and 6 (9.8%) minor strokes. Follow up at a mean of 6 months showed complete occlusion in 33/42 (79%) aneurysms, neck remnants in 5 (12%), and aneurysm remnants in 4 (10%). Conclusions: The results demonstrate comparable acceptable complication rates and angiographic results of the Phenox HPC, which are similar to other flow diverters. Long-term and comparative studies are needed to evaluate the full potential of these devices.

28 October 2026 in Clinical Neuroradiology
Verified
Journal Article
Open access
PDF file
NLNils Lehnen
Nils Lehnen
DBDaniel Böhnert
Daniel Böhnert
DDDrini Dracini
Drini Dracini
MZMatthew Moussa Zidan
Matthew Moussa Zidan
TLTim Lampmann
Tim Lampmann
Franziska DornFranziska Dorn
Franziska Dorn
Purpose: Chronic subdural hematoma (cSDH) has traditionally been treated surgically, with a ~ 20% risk of recurrence. Three RCTs have shown that middle meningeal artery embolization MMAE using EVOH-based liquid embolic agents (LEAs) reduces recurrence. Preliminary data suggest similar results with n -butyl-cyanoacrylate (NBCA). N‑hexyl-Cyanoacrylate (NHCA) may offer advantages over NBCA, but has not been compared with EVOH-based agents. Methods: This retrospective multicenter study included patients from four centers treated with MMAE for cSDH using Squid (EVOH) or Magic Glue (NHCA). The primary endpoint was repeat surgical evacuation. The primary endpoint was analyzed using Kaplan–Meier estimates, the log-rank test, and Cox proportional hazards regression. Univariable and multivariable logistic regression was performed as a complementary adjusted analysis. Secondary endpoints were cSDH thickness reduction, modified Rankin Scale (mRS) at last follow up, and complications. Results: 144 patients were included (120 males, mean age 75.2 ± 10.6 years). NHCA was used in 79 patients (54.9%) and EVOH in 65 (45.1%). In each group, 9 patients required repeat surgical evacuation (NHCA: 11.4% [95%CI: 5.3%, 20.5%], EVOH: 13.8% [95% CI: 6.5%, 24.7%]). Kaplan–Meier analysis showed no significant difference in freedom from repeat surgical evacuation between groups; Cox regression likewise showed no significant association between embolic agent and time to repeat surgery (HR 0.68, 95% CI 0.27–1.72; p = 0.42). Complementary multivariable logistic analysis did not identify a statistically significant association between the embolic agent and repeat surgery (adjusted OR 0.92, 95% CI 0.32–2.63; p = 0.87). Mean cSDH reduction was 12.4 ± 6.1 mm with NHCA and 13.8 ± 7.4 mm with EVOH ( p = 0.18). Median mRS at last follow-up was 1 (IQR: 0, 2) in both groups ( p = 0.64). Complications were reported in 6.3% (Magic Glue) and 4.6% (Squid, OR 1.4, 95% CI 0.3,6.9; p = 0.73). Conclusions: This multicenter study found no statistically significant differences between NHCA and EVOH regarding repeat surgerical evacuation, cSDH reduction, mRS at last follow-up, and safety. However, the wide confidence intervals preclude conclusions of equivalence.